Haploidentical Transplantation: Repurposing Cyclophosphamide

Historically, graft-versus-host disease (GVHD), particularly in the setting of HLA disparity, has constrained the applicability and availability of allogeneic blood or marrow transplantation (BMT). In fact, the search for appropriate alternative donors on behalf of the many potential BMT recipients lacking matched donors could be considered the “holy grail” of the BMT field. Even when a match can be found, National Marrow Donor Program data indicate that a median of 4 months is required to complete searches that result in BMT [1].